INSMED
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chroni... c infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
INSMED
Social Links:
Industry:
Biotechnology Medical Pharmaceutical
Founded:
1988-01-01
Address:
Bridgewater, New Jersey, United States
Country:
United States
Website Url:
http://www.insmed.com
Total Employee:
501+
Status:
Active
Contact:
+1 732) 997-4600
Email Addresses:
[email protected]
Total Funding:
1.37 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2010-12-02 | Transave | Transave acquired by Insmed | N/A |
| 2000-05-31 | Celtrix Pharmaceuticals | Celtrix Pharmaceuticals acquired by Insmed | N/A |
Investors List
Forbion Capital Partners
Forbion Capital Partners investment in Post-IPO Equity - Insmed
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-23 | Insmed Names Drayton Wise Chief Commercial Officer |
| 2020-01-30 | Insmed appoints Bonstein chief financial officer |
Official Site Inspections
http://www.insmed.com Semrush global rank: 2.3 M Semrush visits lastest month: 8.16 K
- Host name: 195.126.196.104.bc.googleusercontent.com
- IP address: 104.196.126.195
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Insmed" on Search Engine
Management Team - Insmed
Our management team has extensive biopharmaceutical experience and a proven track record in research, drug development, and commercialization. The team embodies our …See details»
Investor Relations | Insmed Incorporated
May 9, 2024 Insmed (Nasdaq:INSM) is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our strong and …See details»
2020 Annual Report - Insmed
Started. One year ago, Insmed was a single-product company with a successful U.S. launch and an ambitious vision. Today, we have become a truly global commercial …See details»
Insmed Reports First-Quarter 2024 Financial Results and …
May 9, 2024 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today …See details»
Our Culture - Insmed
Our Mission. To transform the lives of patients with serious and rare diseases. Our Vision. To be a globally recognized leading biotech company that empowers great people to deliver, with a profound sense of urgency …See details»
Insmed Incorporated | LinkedIn
About us. Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases.See details»
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial …
Feb 22, 2024 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today …See details»
Insmed - Crunchbase Company Profile & Funding
Legal Name Insmed Incorporated. Stock Symbol NASDAQ:INSM. Company Type For Profit. Contact Email [email protected]. Phone Number (908) 977 …See details»
Timeline Archive - Insmed
Insmed is founded as a private company by Dr. Joseph Larner in Charlottesville, Va., to develop medicines to treat diabetes. 1997. September 20, 2019 by. Transave is founded …See details»
Culture - annualreport.insmed.com
Insmed. 2023 Annual Report. PDF Downloads Submenu. Full 2023 Annual Report; Proxy; 10-K Report; Menu. Culture. Breakthroughs Begin Here. Our Mission. To transform the …See details»
Insmed Ranks No. 1 on Science's 2023 Top Biopharma …
BRIDGEWATER, N.J., Oct. 26, 2023 / PRNewswire / -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of …See details»
Insmed Reports First-Quarter 2024 Financial Results and …
BRIDGEWATER, N.J., May 9, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients …See details»
Grants and Funding for Scientific Research and More - Insmed
Research projects. Research awards. Charitable donations. Medical sponsorships. Commercial sponsorships. Insmed may provide funding to organizations that support …See details»
Insmed Company Profile, Stock Price, News, Rankings | Fortune
As Insmed's business needs have changed and the organization has evolved, I have been given many, many opportunities to learn and grow with the company. Insmed values not …See details»
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline …
May 10, 2024 Insmed INSM reported a loss of $1.06 per share in the first quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of $1.22. In the year-ago quarter, …See details»
Contact Us - Insmed
Contact Us. Key Contacts. Medical Information. Email. [email protected]. Numbers. US 1-844-4-INSMED ( 1-844-446-7633) Visit insmed.com/med-info for a …See details»
Insmed - Funding, Financials, Valuation & Investors - Crunchbase
Insmed has acquired 3 organizations. Their most recent acquisition was Adrestia Therapeutics on Jun 30, 2023. Unlock for free. Funding Rounds. Number of Funding …See details»
Insmed Inc (INSM) Reports Q1 2024 Earnings: Misses EPS …
6 days ago Revenue: Reported Q1 2024 revenue of $75.5 million, an increase of 16% year-over-year, slightly below the estimate of $77.76 million. Net Loss: Q1 2024 net loss …See details»
Positioning a pharmaceutical company for an expanded future
Insmed is on a mission to transform the lives of patients living with serious and rare diseases with a vision to be a globally recognized leading biotech company that …See details»
Insmed First Quarter 2024 Earnings: EPS Beats Expectations, …
May 10, 2024 Key Financial Results. Revenue: US$75.5m (up 16% from 1Q 2023). Net loss: US$157.1m (loss narrowed by 1.7% from 1Q 2023). US$1.06 loss per share …See details»